Overview
Majda Hadzihametovic, M.D., received her M.D. from University of Belgrade School of Medicine in 2006, followed by Postdoctoral Fellowship at the University of Pennsylvania, Scheie Eye Institute, from 2007 to 2012. After completing a year of General Surgery training at Drexel University College of Medicine in 2012, she completed Ophthalmology Residency at the same institution from 2013 to 2016, where she served as a chief resident during her final year. After finishing Medical Retina training at Duke, in 2017 she joined the faculty.
Dr. Hadziahmetovic’s is a clinician scientist with present research agenda focused on teleophthalmology. She is particularly interested in employing remote diagnosis in early diagnosis, suitable referral and timely treatment of diabetic retinopathy and age-related macular degeneration using cutting-edge noninvasive optic coherence tomography (OCT) imaging and fundus photography.
Dr. Hadziahmetovic also has a great interest in basic science, especially investigating new mouse models of retinal diseases. Her long term goal is better understanding of disease processes in Age related macular degeneration using different animal models and potential reversal of morphological changes.
Current Appointments & Affiliations
Recent Publications
Artificial intelligence in age-related macular degeneration: Advancing diagnosis, prognosis, and treatment.
Journal Article Surv Ophthalmol · September 18, 2025 Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss in older adults. While anti-vascular endothelial growth factor (anti-VEGF) therapy and novel treatments for geographic atrophy have improved management, timely diagnosis ... Full text Link to item CiteTHE EMERGING ROLE AI IN DR SCREENING AI-powered technologies could help ophthalmologists meet the growing needs of this patient population.
Journal Article Retina Today · September 1, 2025 CiteEffect of Faricimab on Visual Acuity and Retinal Structure in Neovascular Age-Related Macular Degeneration Previously Treated With Anti-VEGF Therapy.
Journal Article J Vitreoretin Dis · August 30, 2025 Purpose: To evaluate the effects of switching from traditional antivascular endothelial growth factor (anti-VEGF) therapies to faricimab, a biclonal antibody that targets both VEGF and angiopoietin-2, on eyes with neovascular age-related macular degenerati ... Full text Link to item CiteRecent Grants
A Phase 2 Multicenter, Randomized, Double-masked, Sham-controlled, Reference-arm Study to Evaluate Efficacy and Safety of ONL1204 in Patients With Geographic Atrophy (GA) Associated With Age-related Macular Degeneration (AMD)
Clinical TrialPrincipal Investigator · Awarded by ONL Therapeutics · 2025 - 2030A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-1)
Clinical TrialPrincipal Investigator · Awarded by 4D Molecular Therapeutics · 2025 - 2030A Phase 1/2 Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Clinical TrialPrincipal Investigator · Awarded by Ocugen, Inc. · 2024 - 2029View All Grants